source
- Novo Nordisk CFO sees oral Wegovy rollout boosting outlook and remains upbeat on CagriSemaNovo Nordisk's chief financial officer, Karsten Munk Knudsen, discussed the company's second‑quarter earnings and the progress of the oral Wegovy pill during a recent interview. He highlighted that…
- Replimune secures FDA accelerated approval for melanoma therapy TudriqevReplimune announced that the FDA has granted accelerated approval to its melanoma therapy RP1, marketed as Tudriqev, after two earlier rejections and a third expedited review. The decision reflects…